Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Orelabrutinib||ICP-022|ICP022|ICP 022||BTK inhibitor 22||Orelabrutinib (ICP-022) inhibits BTK, potentially resulting in decreased growth of BTK-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||CLL/SLL||not applicable||Orelabrutinib||Phase II||Actionable||In a Phase II trial, treatment with Orelabrutinib (ICP-022) demonstrated safety and resulted in an objective response rate (ORR) of 88.5% (69/78), including 1 complete response, 39 partial responses, and 29 partial responses with lymphocytosis, and a 6 month duration of response of 89.8% in Chinese patients with relapsed or refractory chronic lymphocytic leukemia/small cell leukemia (Blood (2019) 134 (Supplement_1): 4319).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04014205||Phase I||Orelabrutinib||A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies||Recruiting|